Tumor Progression
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Studies showed that vascular endothelial growth factor (VEGF) and its receptor (VEGFR) have elevated expression in tumors and are involved in tumor progression and metastasis; suggesting their potential for being a therapeutic target.
|
31786193 |
2020 |
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
In addition, expression of phospho-ERK (p-ERK), NF-κB p65 (Ser536), and tumor progression-associated proteins, such as matrix metallopeptidase 9 (MMP-9), vascular endothelial growth factor (VEGF), X-linked inhibitor of apoptosis protein (XIAP), and CyclinD1 were all significantly decreased by magnolol.
|
31714653 |
2020 |
Tumor Progression
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Chondromodulin-1 and vascular endothelial growth factor-A expression in esophageal squamous cell carcinoma: accelerator and brake theory for angiogenesis at the early stage of cancer progression.
|
31595395 |
2020 |
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
An increased level of Nectin-4 along with representative metastatic (CD-44, Sca1, ALDH1, Nanog) and angiogenic (Ang-I, Ang-II, VEGF) markers were noted in metastatic tumors (local and distant) in comparison to primary tumors that were correlated with different grades of tumor progression.
|
31617074 |
2020 |
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Recently, ramucirumab, a drug that targets vascular endothelial growth factor receptor (VEGFR), was clinically approved; therefore, we evaluated VEGFR2 expression and its predictive roles in tumor progression in clear cell renal cell carcinoma (CCRCC).
|
31477752 |
2019 |
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Elevated kindlin-2 promotes tumour progression and angiogenesis through the mTOR/VEGFA pathway in melanoma.
|
31427543 |
2019 |
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
We identify a novel function for OVA66 in regulating an autocrine VEGF-VEGFR2 feed-forward signalling loop that promotes tumour progression and angiogenesis.
|
30833190 |
2019 |
Tumor Progression
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
Neuropilins (NRPs) are cell surface glycoproteins, acting as co-receptors for secreted Semaphorins (SEMAs) and for members of the vascular endothelial growth factor (VEGF) family; they have been initially implicated in axon guidance and angiogenesis regulation, and more recently in cancer progression.
|
31027288 |
2019 |
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Insulin-like growth factor 2 mRNA-binding protein 3 (IMP3) and vascular endothelial growth factor-A (VEGF-A) may play important roles in the process of tumor progression and tumor angiogenesis.
|
31611984 |
2019 |
Tumor Progression
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
To investigate the role of tumor growth velocity in defining tumor progression in metastatic renal cell carcinoma patients treated with the vascular endothelial growth factor tyrosine kinase inhibitor, sorafenib.
|
30325072 |
2019 |
Tumor Progression
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
A negative correlation was determined between miR-548c-3p and hypoxia-inducible factor (HIF) 1α or vascular endothelial growth factor (VEGF) levels, indicating that miR-548c-3p inhibited tumor progression by suppressing the HIF1α-mediated VEGF signaling pathway.
|
31378898 |
2019 |
Tumor Progression
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Sporamin down-regulates the expression and secretion of β-catenin and VEGF in the liver, which subsequently inhibits the transcription of downstream genes involved in cancer progression and angiogenesis.
|
31333311 |
2019 |
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Matrix metalloproteinase-9 (MMP-9) and vascular endothelial growth factor (VEGF-C) are thought to be involved in tumor progression and metastasis.
|
30993496 |
2019 |
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Targeting the activin receptor-like kinase 1 (ALK1) and VEGF pathways simultaneously by combining the ALK1 ligand trap dalantercept with sorafenib may result in more effective angiogenic blockade and delay tumor progression in patients with advanced HCC.Although the combination was generally well tolerated, there was no additive antitumor activity with the combination of dalantercept plus sorafenib in patients with advanced HCC.
|
30352941 |
2019 |
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
VEGF and its receptors play a major role in physiologic and pathologic angiogenesis, which is marked in tumour progression and metastasis development.
|
30499413 |
2018 |
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Peripheral blood plasma or mononuclear cell isolates collected prior to therapy and at weeks 8 and 16 and at time of tumor progression were analyzed for vascular endothelial growth factor and regulatory T-cell (Treg) measurements.
|
29666297 |
2018 |
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Vascular endothelial growth factor (VEGF) and autotaxin (ATX) play important roles in embryonic vasculogenesis and cancer progression.
|
30456868 |
2018 |
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
In the tumors of the nervous system, VEGF plays a critical role in tumor angiogenesis and tumor progression.
|
28911884 |
2018 |
Tumor Progression
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
The low expression of miR‑1 in CRC may be one of the reasons for the abnormally high expression of VEGF; the upregulation of miR‑1 expression may inhibit cancer progression by downregulating VEGF.
|
29845255 |
2018 |
Tumor Progression
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
cMet signaling pathway is involved in the resistance to anti-VEGF therapy and cMet overexpression is associated with tumor progression and poor prognosis.
|
29675102 |
2018 |
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Tumor oxygenation mediated by M-Abx specifically occurs within the H2O2-overexpressed tumor microenvironment, and significantly downregulates the content of tumor progression-related proteins, such as HIF-1α, P-gp, and VEGF.
|
30420976 |
2018 |
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Photodynamic therapy (PDT), eliminates not only the tumor, but also modulates signaling factors release, e.g. vascular endothelial growth factor (VEGF), which plays a crucial role in cancer progression.
|
29079348 |
2018 |
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
VEGF-A and angiopoetin-2 clearly play a role as mediators of the vasculogenesis contributing to tumor progression.
|
29397265 |
2018 |
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Vascular endothelial growth factor (VEGF) and VEGF receptor 2 (VEGFR2) are increased in majority species of cancers and suppress tumor progression by blocking VEGF/VEGFR2.
|
30400838 |
2018 |
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Hypoxia-inducible factor-1 (HIF-1) and vascular endothelial growth factor (VEGF) play important roles in cancer progression in various cancer cell lines.
|
29630948 |
2018 |